MRgFUS and RFA for Treatment of Facet-joint Osteoarthritis Low Back Pain

Chronic Low Back Pain Clinical Trial

Official title:

Comparative Study of Magnetic Resonance-guided Focused Ultrasound and Radiofrequency Ablation for Treatment of Facet-joint Osteoarthritis Low Back Pain

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03168802
• Other study ID #: N201609021
• Status: Recruiting
• Phase: N/A
• Start date: August 24, 2018
• Est. completion date: November 9, 2024

Study information

• Verified date: November 2023
• Source: Taipei Medical University Hospital
• Contact: Meng-Huang Wu, MD
• Phone: 227372181
• Email: maxwutmu[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, randomized, two-arm, phase II study. The purpose of this study is: - To evaluate and compare the efficacy and safety of magnetic resonance-guided focused ultrasound (MRgFUS) and radiofrequency ablation (RFA) for treatment of facet-joint osteoarthritis low back pain. - Determining the effect of the MRgFUS System and RFA for improving functional disabilities and in reducing pain resulting from facet-joint osteoarthritis low back pain. Efficacy will be determined by the level of pain relief (as measured by the Numerical Rating Scale, NRS), decrease in analgesics/opiate, improved quality of life (as measured by the Oswestry Disability Questionnaire, ODQ, and core outcome measures index questionnaire, COMI), pain interference with function (as measured by the Brief Pain Inventory-Interference scale, BPI-QoL), general health status (as measured by the EQ5D), physical exam, X-ray and MRI studies from baseline up to 12-Months post- MRgFUS and radiofrequency treatment. - Evaluate incidence and severity of adverse events associated with the MRgFUS system and RFA used for the treatment of pain resulting from facet-joint osteoarthritis low back pain.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: November 9, 2024
• Est. primary completion date: November 9, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 79 Years

Eligibility

Inclusion Criteria:

1. Men and women age 20 to 79 years old

2. Suffering from lumbar vertebral facet joint syndrome.

3. Lower back pain at least six months (NRS=4).

4. Conventional treatment of pain includes NSAIDs, opioids, muscle relaxants, oral steroids, physical therapy or chiropractic therapy.

5. Imaging of the spine have facet osteoarthritis.

6. Referred pain is no more below the knee.

7. At least once when local anesthesia or diagnostic medial nerve branch injection, pain reduction> 75% (0.5ml of 2% lidocaine).

Exclusion Criteria:

1. Patients with evidence of lumbosacral radiculopathy on MRI, CT or physical exam findings, including radicular leg pain.

2. Patients with motor deficit or any other indication for surgical intervention.

3. Patients with MRgFUS or RF treatment for LBP within the last 6 months.

4. Patients with previous low back surgery.

5. Patients who are pregnant.

6. Patients with existing malignancy.

7. Patients with allergies to relevant contrast, anesthetics, sedation drugs.

8. Patients with contraindications for MRI.

9. Patients with an acute medical condition (e.g., pneumonia, sepsis) that is expected to hinder them from completing this study.

10. Patients with unstable cardiac status including:

• Unstable angina pectoris on medication
• Patients with documented myocardial infarction less than 40 days prior to protocol enrolment
• Patients with Severe Congestive Heart Failure, NYHA class 4.
• Patients on anti-arrhythmic drugs or with uncontrolled and/or untreated arrhythmia status
• Patients with pacemaker

11. Patients with severe cerebrovascular disease (CVA within last 6 months)

12. Patients with severe hypertension (diastolic BP > 100 on medication)

13. Patients with an active infection or severe hematological, neurological, or other uncontrolled disease.

14. Patients unable to communicate with the investigator and staff.

15. Patients who are not able or willing to tolerate the required prolonged stationary position during treatment (approximately 2 hrs.)

16. Coagulation disorders or other bleeding disorders, use of anticoagulants or antiplatelet drugs within 5 days before treatment.

17. When local anesthesia or diagnostic medial nerve branch injection, the pain does not reach 75% (0.5 mL of 2% lidocaine).

Related Conditions & MeSH terms

• Back Pain
• Chronic Low Back Pain
• Facet Joint Syndrome
• Low Back Pain
• Osteoarthritis

Intervention

Procedure:
• MRgFUS ablation
Focus ultrasound ablation therapy under MRI navigation for facet joint syndrome.
• Radiofrequency ablation
Radiofrequency ablation therapy under C-arm navigation for facet joint syndrome.

Locations

Country	Name	City	State
Taiwan	Taipei medical university hospital	Taipei	Please Select

Sponsors (1)

Lead Sponsor	Collaborator
Taipei Medical University Hospital

Country where clinical trial is conducted

Taiwan, 

References & Publications (4)

Kaye EA, Monette S, Srimathveeravalli G, Maybody M, Solomon SB, Gulati A. MRI-guided focused ultrasound ablation of lumbar medial branch nerve: Feasibility and safety study in a swine model. Int J Hyperthermia. 2016 Nov;32(7):786-94. doi: 10.1080/02656736.2016.1197972. Epub 2016 Jul 21. — View Citation

Krug R, Do L, Rieke V, Wilson MW, Saeed M. Evaluation of MRI protocols for the assessment of lumbar facet joints after MR-guided focused ultrasound treatment. J Ther Ultrasound. 2016 Apr 6;4:14. doi: 10.1186/s40349-016-0057-8. eCollection 2016. — View Citation

Maas ET, Ostelo RW, Niemisto L, Jousimaa J, Hurri H, Malmivaara A, van Tulder MW. Radiofrequency denervation for chronic low back pain. Cochrane Database Syst Rev. 2015 Oct 23;2015(10):CD008572. doi: 10.1002/14651858.CD008572.pub2. — View Citation

Weeks EM, Platt MW, Gedroyc W. MRI-guided focused ultrasound (MRgFUS) to treat facet joint osteoarthritis low back pain--case series of an innovative new technique. Eur Radiol. 2012 Dec;22(12):2822-35. doi: 10.1007/s00330-012-2628-6. Epub 2012 Aug 31. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Physical exams for back range of motion	Efficacy	1-, 4-, 8-, 12-, 24-, 36-, 52-week post-treatment
Other	X-ray for spine facet change	Efficacy	1-, 4-, 8-, 12-, 24-, 36-, 52-week post-treatment
Primary	Pain score change: Numerical Rating Scale (NRS)	Efficacy	24-week post-treatment
Secondary	Pain score change: Numerical Rating Scale (NRS)	Efficacy	1-, 4-, 8-, 12-, 36-, 52-week post-treatment
Secondary	Functional scales change: Brief Pain Inventory-Quality of Life (BPI-QoL)	Efficacy	1-, 4-, 8-, 12-, 24-, 36-, 52-week post-treatment
Secondary	Functional scales change: Oswestry Disability Questionnaire (ODQ)	Efficacy	1-, 4-, 8-, 12-, 24-, 36-, 52-week post-treatment
Secondary	Functional scales change: Core Outcome Measurement Index (COMI)	Efficacy	1-, 4-, 8-, 12-, 24-, 36-, 52-week post-treatment
Secondary	Functional scales change: EQ5D Quality of Life questionnaires	Efficacy	1-, 4-, 8-, 12-, 24-, 36-, 52-week post-treatment
Secondary	Amount of analgesic consumption	Efficacy	1-, 4-, 8-, 12-, 24-, 36-, 52-week post-treatment
Secondary	Adverse event	Safety	1-, 4-, 8-, 12-, 24-, 36-, 52-week post-treatment